Clinical Research, Pharma & Healthcare FinancingOmeros Provides Update on Zaltenibart Phase 3 PNH TrialBusiness WireMarch 24, 2025March 25, 2025 by Business WireMarch 24, 2025March 25, 2025093 — Phase 3 Data Needed for BLA Submission Expected in the Fourth Quarter 2026 — Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site...
